Safety of Intranasal Ketamine for Reducing Uncontrolled Cancer-Related Pain: Protocol of a Phase I/II Clinical Trial

Jack W Shteamer, R Donald Harvey, Boris Spektor, Kimberly Curseen, Katherine Egan, Zhengjia Chen, Theresa W Gillespie, Roman M Sniecinski, Vinita Singh, Jack W Shteamer, R Donald Harvey, Boris Spektor, Kimberly Curseen, Katherine Egan, Zhengjia Chen, Theresa W Gillespie, Roman M Sniecinski, Vinita Singh

Abstract

Background: Approximately 12 million Americans are affected with cancer. Of these, 53% experience pain at all stages of cancer. Pain may remain uncontrolled despite high-dose opioid therapy, and opioids have many well-documented harmful side effects. Intranasal ketamine has been shown to be effective in controlling breakthrough noncancer pain in a double-blind randomized control trial (DBRCT) by Carr et al in 2003 as well as to help with depression in a DBRCT by Lapidus et al in 2014. We seek to obtain preliminary data on the safety, feasibility, and utility of this novel technique for the treatment of uncontrolled cancer pain.

Objective: This study aimed to obtain preliminary data via a clinical trial addressing the safety, feasibility, pharmacokinetics, and pharmacodynamics of intranasal ketamine. These initial findings will be applied to a subsequent trial to determine the effectiveness and associated toxicities of ketamine in a larger sample of cancer patients and to address the compelling need to identify new, successful management therapies for cancer pain.

Methods: This is an institutional review board- and investigational new drug-approved, prospective phase I/II trial to investigate the safety and use of intranasal ketamine in patients with uncontrolled pain related to cancer or cancer treatment. Informed consent will be obtained prior to all study procedures. All patients will be assigned to the same investigational treatment arm. After patient selection via inclusion/exclusion criteria, patients will be seen over 5 visits, with each visit conducted 2-7 days apart. Patients will be administered ketamine on visits 1-4 and monitored for 240 minutes with continuous pulse oximetry and regular blood pressure checks. Blood samples as well as patient-reported outcomes will be collected at set time points at baseline and after drug delivery. Patients will receive 10 mg intranasal ketamine on visit 1, 10 mg intravenous ketamine on visit 2, 30 mg intranasal ketamine on visit 3, and 50 mg intranasal ketamine on visit 4. On visit 5, an addition blood sample will be drawn.

Results: As of March 2019, enrollment is in progress, and a total of 7 subjects have completed the study. Enrollment is expected to be completed by April 2019. Final data analysis will commence soon after, and the results are expected to be submitted for publication in 2019.

Conclusions: If intranasal ketamine can be utilized for pain control in cancer patients, it could provide superior analgesia and better quality of life, without the risk of significant respiratory depression and constipation associated with opioid medications. These findings will be an important initial step toward testing the effectiveness of intranasal ketamine as a nonopioid medication for cancer pain and as potential maintenance outpatient therapy.

Trial registration: ClinicalTrials.gov NCT03146806; https://ichgcp.net/clinical-trials-registry/NCT03146806.

International registered report identifier (irrid): DERR1-10.2196/12125.

Keywords: cancer pain; chronic pain; intranasal ketamine.

Conflict of interest statement

Conflicts of Interest: None declared.

©Jack W Shteamer, R Donald Harvey, Boris Spektor, Kimberly Curseen, Katherine Egan, Zhengjia Chen, Theresa W Gillespie, Roman M Sniecinski, Vinita Singh. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.04.2019.

Figures

Figure 1
Figure 1
Participant timeline. PK: pharmacokinetic; PD: pharmacodynamic; VAS: Visual Analoge Scale; MADRS: Montgomery Asberg Depression Rating Scale.

References

    1. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007 Sep;18(9):1437–49. doi: 10.1093/annonc/mdm056.
    1. Yakovlev AE, Ellias Y. Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clin Med Res. 2008 Dec;6(3-4):103–6. doi: 10.3121/cmr.2008.813.
    1. Sloan P, Melzack R. Long-term patterns of morphine dosage and pain intensity among cancer patients. Hosp J. 1999;14(2):35–47.
    1. Peng L, Min S, Zejun Z, Wei K, Bennett MI. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. 2015 Jun 29;(6):CD009389. doi: 10.1002/14651858.CD009389.pub3.
    1. Larcher A, Laulin JP, Celerier E, Le Moal M, Simonnet G. Acute tolerance associated with a single opiate administration: involvement of N-methyl-D-aspartate-dependent pain facilitatory systems. Neuroscience. 1998 May;84(2):583–9.
    1. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth. 1996 Aug;77(2):203–7.
    1. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989 Mar;36(2):186–97. doi: 10.1007/BF03011442.
    1. White P, Way WL, Trevor AJ. Ketamine--its pharmacology and therapeutic uses. Anesthesiology. 1982 Feb;56(2):119–36.
    1. Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand. 2002 Aug;46(7):759–70.
    1. Singh V, Gillespie TW, Harvey RD. Intranasal ketamine and its potential role in cancer-related pain. Pharmacotherapy. 2018 Dec;38(3):390–401. doi: 10.1002/phar.2090.
    1. Carr DB, Goudas LC, Denman WT, Brookoff D, Staats PS, Brennen L, Green G, Albin R, Hamilton D, Rogers MC, Firestone L, Lavin PT, Mermelstein F. Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study. Pain. 2004 Mar;108(1-2):17–27. doi: 10.1016/j.pain.2003.07.001.
    1. Lapidus KAB, Levitch CF, Perez AM, Brallier JW, Parides MK, Soleimani L, Feder A, Iosifescu DV, Charney DS, Murrough JW. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry. 2014 Dec 15;76(12):970–6. doi: 10.1016/j.biopsych.2014.03.026.
    1. Bell R, Eccleston C, Kalso E. Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review. J Pain Symptom Manage. 2003 Sep;26(3):867–75.
    1. Christensen K, Rogers E, Green GA, Hamilton DA, Mermelstein F, Liao E, Wright C, Carr DB. Safety and efficacy of intranasal ketamine for acute postoperative pain. Acute Pain. 2007 Dec;9(4):183–192. doi: 10.1016/j.acpain.2007.09.001.
    1. Ferreira-Valente MA, Pais-Ribeiro JL, Jensen MP. Validity of four pain intensity rating scales. Pain. 2011 Oct;152(10):2399–404. doi: 10.1016/j.pain.2011.07.005.
    1. Hjermstad MJ, Fayers PM, Haugen DF, Caraceni A, Hanks GW, Loge JH, Fainsinger R, Aass N, Kaasa S. Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. Journal of Pain and Symptom Management. 2011 Jun;41(6):1073–1093. doi: 10.1016/j.jpainsymman.2010.08.016.
    1. Bombardier C, Hayden J, Beaton DE. Minimal clinically important difference. Low back pain: outcome measures. J Rheumatol. 2001 Feb;28(2):431–8.
    1. Lee J, Hobden E, Stiell UG, Wells GA. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med. 2003 Oct;10(10):1128–30.
    1. van der Roer N, Ostelo RWJG, Bekkering GE, van Tulder MW, de Vet HCW. Minimal clinically important change for pain intensity, functional status, and general health status in patients with nonspecific low back pain. Spine (Phila Pa 1976) 2006 Mar 01;31(5):578–82. doi: 10.1097/01.brs.0000201293.57439.47.
    1. Kovacs FM, Abraira V, Royuela A, Corcoll J, Alegre L, Cano A, Muriel A, Zamora J, del Real MTG, Gestoso M, Mufraggi N. Minimal clinically important change for pain intensity and disability in patients with nonspecific low back pain. Spine (Phila Pa 1976) 2007 Dec 01;32(25):2915–20. doi: 10.1097/BRS.0b013e31815b75ae.
    1. Kovacs F, Abraira V, Royuela A, Corcoll J, Alegre L, Tomás M, Mir MA, Cano A, Muriel A, Zamora J, Del Real MTG, Gestoso M, Mufraggi N, Spanish Back Pain Research Network Minimum detectable and minimal clinically important changes for pain in patients with nonspecific neck pain. BMC Musculoskelet Disord. 2008 Apr 10;9:43. doi: 10.1186/1471-2474-9-43.
    1. Farrar J, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001 Nov;94(2):149–58.
    1. Montgomery S, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382–9.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj